hydralazine has been researched along with Bright Disease in 63 studies
Hydralazine: A direct-acting vasodilator that is used as an antihypertensive agent.
hydralazine : The 1-hydrazino derivative of phthalazine; a direct-acting vasodilator that is used as an antihypertensive agent.
Bright Disease: A historical classification which is no longer used. It described acute glomerulonephritis, acute nephritic syndrome, or acute nephritis. Named for Richard Bright.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hydralazine, a widely used therapy for hypertension and heart failure, can elicit autoimmune disease, including anti-neutrophil cytoplasmic antibody associated glomerulonephritis (ANCA-GN)." | 8.02 | Anti-neutrophil cytoplasmic antibody associated glomerulonephritis complicating treatment with hydralazine. ( Appel, GB; Batal, I; Bomback, AS; Canetta, PA; D'Agati, VD; Kudose, S; Markowitz, GS; Radhakrishnan, J; Santoriello, D; Stokes, MB, 2021) |
| "Hydralazine is a common vasodilator which has been used for the treatment of hypertension and heart failure." | 7.96 | Hydralazine-induced antineutrophil cytoplasmic antibody-associated vasculitis with pulmonary-renal syndrome: a case report. ( Al-Abdouh, A; Bekele, A; Garcia, P; Seid, H; Siyal, AM, 2020) |
| "We report a rare case of Hydralazine-induced ANCA associated glomerulonephritis with alveolar hemorrhage in the setting of acute Clostridium Difficile Infection." | 7.83 | Hydralazine-Induced ANCA Vasculitis in the Setting of Acute Clostridium Difficile Infection. ( Cucu, DF; El Meligy, A; Rasla, S, 2016) |
| "Hydralazine is a medication that has been used to manage hypertension and heart failure." | 7.80 | Hydralazine associated pauci-immune glomerulonephritis. ( Baiswar, S; Suneja, M; Vogelgesang, SA, 2014) |
| "We report a case of hydralazine-induced alveolar hemorrhage and anti-neutrophil cytoplasmic antibody (ANCA)-positive pauci-immune glomerulonephritis, with serum anti-histone antibodies present, features not previously described in the literature with this drug." | 7.75 | Hydralazine-induced ANCA-positive pauci-immune glomerulonephritis: a case report and literature review. ( Dobre, M; Negrea, L; Wish, J, 2009) |
| "We have undertaken an investigation retrospectively of 21 patients with positive antinuclear antibodies, who had been on hydralazine treatment and developed a glomerulonephritis." | 7.69 | Occurrence of autoantibodies directed against myeloperoxidase and elastase in patients treated with hydralazine and presenting with glomerulonephritis. ( Nässberger, L; Thysell, H; Torffvit, O, 1994) |
| "Autoantibodies against myeloperoxidase and elastase were found in a study of nine patients who had developed glomerulonephritis after treatment with hydralazine, but not in patients who were treated with hydralazine without side-effects." | 7.68 | Antibodies to neutrophil granulocyte myeloperoxidase and elastase: autoimmune responses in glomerulonephritis due to hydralazine treatment. ( Björck, S; Johansson, AC; Nässberger, L; Sjöholm, AG, 1991) |
| " Immune complex glomerulonephritis has been demonstrated in a few cases of SLE following procainamide or anticonvulsant therapy but has not been documented in association with hydralazine-induced SLE despite the recognition of this syndrome 30 years ago." | 7.67 | Immune complex glomerulonephritis in hydralazine-induced SLE. ( Harrington, JT; Levey, AS; Pinn, VW; Shapiro, KS, 1984) |
| "Nine patients (6 men, 3 women) with rapidly progressive glomerulonephritis developing during hydralazine therapy were seen." | 7.67 | Hydralazine-associated glomerulonephritis. ( Björck, S; Svalander, C; Westberg, G, 1985) |
| "Hydralazine-induced lupus was first described in 1953." | 5.48 | Hydralazine-associated antineutrophil cytoplasmic antibody vasculitis with pulmonary-renal syndrome. ( Aeddula, NR; Ansari, A; Juran, PJ; Pathireddy, S, 2018) |
| "Hydralazine, an arterial vasodilator, is a widely used medication for the management of hypertension and heart failure, especially for patients who cannot tolerate the use of ACEIs or ARBs." | 5.12 | Hydralazine-Induced ANCA Associated Vasculitis (AAV) Presenting with Pulmonary-Renal Syndrome (PRS): A Case Report with Literature Review. ( Al-Sadawi, M; Battisha, A; Doughem, K; Konduru, L; Madoukh, B; Shaikh, S; Sheikh, O, 2021) |
| " We present a patient with hydralazine-induced antineutrophil cytoplasmic antibodies-positive vasculitis with a pulmonary-renal syndrome manifesting as pauci-immune glomerulonephritis and alveolar haemorrhage." | 4.31 | Diagnostic dilemma: drug-induced vasculitis versus systemic vasculitis. ( Acharya, I; Arend, LJ; Smith, LW; Weisman, DS, 2023) |
| "Hydralazine, a widely used therapy for hypertension and heart failure, can elicit autoimmune disease, including anti-neutrophil cytoplasmic antibody associated glomerulonephritis (ANCA-GN)." | 4.02 | Anti-neutrophil cytoplasmic antibody associated glomerulonephritis complicating treatment with hydralazine. ( Appel, GB; Batal, I; Bomback, AS; Canetta, PA; D'Agati, VD; Kudose, S; Markowitz, GS; Radhakrishnan, J; Santoriello, D; Stokes, MB, 2021) |
| "Hydralazine is a common vasodilator which has been used for the treatment of hypertension and heart failure." | 3.96 | Hydralazine-induced antineutrophil cytoplasmic antibody-associated vasculitis with pulmonary-renal syndrome: a case report. ( Al-Abdouh, A; Bekele, A; Garcia, P; Seid, H; Siyal, AM, 2020) |
| "We report a rare case of Hydralazine-induced ANCA associated glomerulonephritis with alveolar hemorrhage in the setting of acute Clostridium Difficile Infection." | 3.83 | Hydralazine-Induced ANCA Vasculitis in the Setting of Acute Clostridium Difficile Infection. ( Cucu, DF; El Meligy, A; Rasla, S, 2016) |
| "Hydralazine is a medication that has been used to manage hypertension and heart failure." | 3.80 | Hydralazine associated pauci-immune glomerulonephritis. ( Baiswar, S; Suneja, M; Vogelgesang, SA, 2014) |
| "We report a case of hydralazine-induced alveolar hemorrhage and anti-neutrophil cytoplasmic antibody (ANCA)-positive pauci-immune glomerulonephritis, with serum anti-histone antibodies present, features not previously described in the literature with this drug." | 3.75 | Hydralazine-induced ANCA-positive pauci-immune glomerulonephritis: a case report and literature review. ( Dobre, M; Negrea, L; Wish, J, 2009) |
| " After 4 weeks of DOCA-salt hypertension, rats were either killed (n = 6), or treated with a non-hypotensive dose of spironolactone (n = 7) or triple therapy (hydrochlorothiazide, reserpine and hydralazine, n = 8) to normalize blood pressure or with vehicle (n = 19) for two further weeks." | 3.74 | Blood pressure versus direct mineralocorticoid effects on kidney inflammation and fibrosis in DOCA-salt hypertension. ( Cordasic, N; Hartner, A; Hilgers, KF; Klanke, B; Schmieder, RE; Veelken, R, 2008) |
| "We have undertaken an investigation retrospectively of 21 patients with positive antinuclear antibodies, who had been on hydralazine treatment and developed a glomerulonephritis." | 3.69 | Occurrence of autoantibodies directed against myeloperoxidase and elastase in patients treated with hydralazine and presenting with glomerulonephritis. ( Nässberger, L; Thysell, H; Torffvit, O, 1994) |
| "Autoantibodies against myeloperoxidase and elastase were found in a study of nine patients who had developed glomerulonephritis after treatment with hydralazine, but not in patients who were treated with hydralazine without side-effects." | 3.68 | Antibodies to neutrophil granulocyte myeloperoxidase and elastase: autoimmune responses in glomerulonephritis due to hydralazine treatment. ( Björck, S; Johansson, AC; Nässberger, L; Sjöholm, AG, 1991) |
| " Immune complex glomerulonephritis has been demonstrated in a few cases of SLE following procainamide or anticonvulsant therapy but has not been documented in association with hydralazine-induced SLE despite the recognition of this syndrome 30 years ago." | 3.67 | Immune complex glomerulonephritis in hydralazine-induced SLE. ( Harrington, JT; Levey, AS; Pinn, VW; Shapiro, KS, 1984) |
| "Chronic administration of nitrendipine (N) prevented the development of serious renal damage in Wistar rats with experimental glomerulonephritis." | 3.67 | Comparison of BAY e 5009 (nitrendipine) with dihydralazine in Wistar rats with experimentally induced nephritis. ( Mohácsi, G; Sonkodi, S, 1988) |
| "Two patients with rapidly progressive glomerulonephritis associated with hydralazine are reported." | 3.67 | Rapidly progressive nephritis in patients taking hydralazine. ( Lockwood, CM; Mason, PD, 1986) |
| "Nine patients (6 men, 3 women) with rapidly progressive glomerulonephritis developing during hydralazine therapy were seen." | 3.67 | Hydralazine-associated glomerulonephritis. ( Björck, S; Svalander, C; Westberg, G, 1985) |
| "Hydralazine-induced lupus was first described in 1953." | 1.48 | Hydralazine-associated antineutrophil cytoplasmic antibody vasculitis with pulmonary-renal syndrome. ( Aeddula, NR; Ansari, A; Juran, PJ; Pathireddy, S, 2018) |
| "Hydralazine is a commonly used drug for treatment of hypertension and is known to cause drug-induced lupus erythematosus." | 1.38 | Hydralazine-induced ANCA vasculitis with pulmonary renal syndrome: a rare clinical presentation. ( Kaw, D; Malhotra, D; Marina, VP, 2012) |
| "Treatment with captopril also reduced the development of glomerular sclerosis." | 1.29 | Effects of captopril and hydralazine on progression of adriamycin nephropathy in spontaneously hypertensive rats. ( Bogdanovic, G; Djukanovic, L; Jovanovic, D; Kartaljevic, G; Starcevic, A; Susic, D; Varagic, J, 1994) |
| "Six women with hypertension are described who developed an immune complex glomerulonephritis after taking 50-300 mg hydralazine daily for 6 months to 7 years." | 1.27 | Hydralazine and lupus nephritis. ( Dowling, JP; Ihle, BU; Kincaid-Smith, P; Whitworth, JA, 1984) |
| "Propranolol was given to 10 hypertensive patients with CGN and hypotensive effect on renal function was observed." | 1.25 | Therapy and prognosis of hypertension in chronic nephritis. ( Kajiwara, N, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 42 (66.67) | 18.7374 |
| 1990's | 7 (11.11) | 18.2507 |
| 2000's | 2 (3.17) | 29.6817 |
| 2010's | 7 (11.11) | 24.3611 |
| 2020's | 5 (7.94) | 2.80 |
| Authors | Studies |
|---|---|
| Acharya, I | 1 |
| Weisman, DS | 1 |
| Smith, LW | 1 |
| Arend, LJ | 1 |
| Al-Abdouh, A | 1 |
| Siyal, AM | 1 |
| Seid, H | 1 |
| Bekele, A | 1 |
| Garcia, P | 1 |
| Doughem, K | 1 |
| Battisha, A | 1 |
| Sheikh, O | 1 |
| Konduru, L | 1 |
| Madoukh, B | 1 |
| Al-Sadawi, M | 1 |
| Shaikh, S | 1 |
| Santoriello, D | 1 |
| Bomback, AS | 2 |
| Kudose, S | 1 |
| Batal, I | 1 |
| Stokes, MB | 1 |
| Canetta, PA | 1 |
| Radhakrishnan, J | 1 |
| Appel, GB | 1 |
| D'Agati, VD | 1 |
| Markowitz, GS | 1 |
| Tu, W | 1 |
| Fayman, B | 1 |
| Ward, SC | 1 |
| Mamoon, Y | 1 |
| Bandagi, SS | 1 |
| Aeddula, NR | 1 |
| Pathireddy, S | 1 |
| Ansari, A | 1 |
| Juran, PJ | 1 |
| Suneja, M | 1 |
| Baiswar, S | 1 |
| Vogelgesang, SA | 1 |
| Rasla, S | 1 |
| El Meligy, A | 1 |
| Cucu, DF | 1 |
| Klanke, B | 1 |
| Cordasic, N | 1 |
| Hartner, A | 1 |
| Schmieder, RE | 1 |
| Veelken, R | 1 |
| Hilgers, KF | 1 |
| Dobre, M | 1 |
| Wish, J | 1 |
| Negrea, L | 1 |
| Kalra, A | 1 |
| Yokogawa, N | 1 |
| Raja, H | 1 |
| Palaniswamy, C | 1 |
| Desai, P | 1 |
| Zanotti-Cavazzoni, SL | 1 |
| Rajaram, SS | 1 |
| Leelahavanichkul, A | 1 |
| Yan, Q | 1 |
| Hu, X | 1 |
| Eisner, C | 1 |
| Huang, Y | 1 |
| Chen, R | 1 |
| Mizel, D | 1 |
| Zhou, H | 1 |
| Wright, EC | 1 |
| Kopp, JB | 1 |
| Schnermann, J | 1 |
| Yuen, PS | 1 |
| Star, RA | 1 |
| Marina, VP | 1 |
| Malhotra, D | 1 |
| Kaw, D | 1 |
| FIASCHI, E | 1 |
| GRASSI, B | 1 |
| ANDRES, G | 1 |
| DYK, T | 1 |
| VILLARROEL, L | 1 |
| CID, L | 1 |
| HERNANDEZ, R | 1 |
| OYARCE, P | 1 |
| JAMES, JA | 1 |
| FINK, CW | 1 |
| KROGSGAARD, AR | 1 |
| BENDERLY, A | 1 |
| WEAVER, KH | 1 |
| DODGE, WF | 1 |
| TRAVIS, LB | 1 |
| FARIDAY, EE | 1 |
| DAVID, JK | 1 |
| MCQUIGGAN, MC | 1 |
| OLIVER, WJ | 1 |
| LITTLER, ER | 1 |
| CERNY, JC | 1 |
| MEIRING, PD | 1 |
| SMITH, FG | 1 |
| LITMAN, N | 1 |
| LATTA, H | 1 |
| REUBI, F | 1 |
| GOSSWEILER, N | 1 |
| GUERTLER, R | 1 |
| HUBER, A | 1 |
| SCHMID, M | 1 |
| Thiele, KG | 1 |
| Muehrcke, RC | 1 |
| Berning, H | 1 |
| Björck, S | 4 |
| Westberg, G | 3 |
| Svalander, C | 3 |
| Mulec, H | 1 |
| Kincaid-Smith, P | 2 |
| Whitworth, JA | 2 |
| Shapiro, KS | 1 |
| Pinn, VW | 1 |
| Harrington, JT | 1 |
| Levey, AS | 1 |
| Ihle, BU | 1 |
| Dowling, JP | 1 |
| Naparstek, Y | 1 |
| Kopolovic, J | 1 |
| Tur-Kaspa, R | 1 |
| Rubinger, D | 1 |
| Torffvit, O | 1 |
| Thysell, H | 1 |
| Nässberger, L | 3 |
| Djukanovic, L | 1 |
| Susic, D | 1 |
| Jovanovic, D | 2 |
| Varagic, J | 1 |
| Starcevic, A | 1 |
| Kartaljevic, G | 1 |
| Bogdanovic, G | 1 |
| Cambridge, G | 1 |
| Wallace, H | 1 |
| Bernstein, RM | 1 |
| Leaker, B | 1 |
| Yamamoto, M | 1 |
| Fukui, M | 1 |
| Shou, I | 1 |
| Wang, LN | 1 |
| Sekizuka, K | 1 |
| Suzuki, S | 1 |
| Shirato, I | 1 |
| Tomino, Y | 1 |
| Börner, H | 1 |
| Teichmann, G | 1 |
| Kajiwara, N | 1 |
| Johansson, AC | 1 |
| Sjöholm, AG | 1 |
| Thompson, CH | 1 |
| Kalowski, S | 1 |
| Mohácsi, G | 1 |
| Sonkodi, S | 1 |
| Yoshida, Y | 1 |
| Kawamura, T | 1 |
| Ikoma, M | 1 |
| Fogo, A | 1 |
| Ichikawa, I | 1 |
| Feld, LG | 1 |
| Noble, B | 1 |
| Springate, JE | 1 |
| Feldman, MJ | 1 |
| Van Liew, JB | 1 |
| Raij, L | 1 |
| Chiou, XC | 1 |
| Owens, R | 1 |
| Wrigley, B | 1 |
| Widgren, B | 1 |
| Berglund, G | 1 |
| Andersson, OK | 2 |
| Mason, PD | 1 |
| Lockwood, CM | 1 |
| Widgren, BR | 1 |
| Berglund, GL | 1 |
| Abella, R | 1 |
| Blondeel, NJ | 1 |
| Roguska, J | 1 |
| Walker, C | 1 |
| Simon, NM | 1 |
| Del Greco, F | 1 |
| Rorive, G | 1 |
| Loggie, JM | 1 |
| Moser, M | 1 |
| Vaidya, RA | 1 |
| Vaidya, AB | 1 |
| Van Woert, MH | 1 |
| Kase, NG | 1 |
| Mattern, WD | 1 |
| Sommers, SC | 1 |
| Kassirer, JP | 1 |
| Retan, JW | 1 |
| Dillon, HC | 1 |
| Vertes, V | 1 |
| Cangiano, JL | 1 |
| Berman, LB | 1 |
| Gould, A | 1 |
| Hutchings, RH | 1 |
| Hickman, R | 1 |
| Scribner, BH | 1 |
4 reviews available for hydralazine and Bright Disease
| Article | Year |
|---|---|
Hydralazine-Induced ANCA Associated Vasculitis (AAV) Presenting with Pulmonary-Renal Syndrome (PRS): A Case Report with Literature Review.
Topics: Aged; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Female; Glomerulonephritis; Heart | 2021 |
ACUTE GLOMERULONEPHRITIS: REVIEW OF RECENT ADVANCES.
Topics: Antibodies; Child; Drug Therapy; Glomerulonephritis; Hemodynamics; Humans; Hydralazine; Pathology; P | 1964 |
Hypertension in children and adolescents. II. Drug therapy.
Topics: Age Factors; Antihypertensive Agents; Blood Pressure Determination; Child; Chlorothiazide; Chronic D | 1969 |
Treatment of "hypertensive encephalopathy" (accelerated hypertension). II.
Topics: Antihypertensive Agents; Diazoxide; Glomerulonephritis; Guanethidine; Humans; Hydralazine; Hypertens | 1969 |
1 trial available for hydralazine and Bright Disease
| Article | Year |
|---|---|
Effects of treatment on morbidity in hypertension. 3. Influence of age, diastolic pressure, and prior cardiovascular disease; further analysis of side effects.
Topics: Adult; Age Factors; Aged; Aneurysm; Atrial Fibrillation; Blood Glucose; Blood Pressure; Cerebrovascu | 1972 |
58 other studies available for hydralazine and Bright Disease
| Article | Year |
|---|---|
Diagnostic dilemma: drug-induced vasculitis versus systemic vasculitis.
Topics: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Antineutrophil Cytoplasmic; | 2023 |
Hydralazine-induced antineutrophil cytoplasmic antibody-associated vasculitis with pulmonary-renal syndrome: a case report.
Topics: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Female; Glomerulonephritis; Hemorrhage; | 2020 |
Anti-neutrophil cytoplasmic antibody associated glomerulonephritis complicating treatment with hydralazine.
Topics: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Antineutrophil Cytoplasmic; | 2021 |
Hydralazine-Induced Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Asymptomatic and Renal-Restricted Presentation.
Topics: Aged; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Antineutrophil Cytopla | 2021 |
Hydralazine-associated antineutrophil cytoplasmic antibody vasculitis with pulmonary-renal syndrome.
Topics: Aged; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Biopsy; Blood Protein Electrophore | 2018 |
Hydralazine associated pauci-immune glomerulonephritis.
Topics: Aged; Aged, 80 and over; Amlodipine; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Ant | 2014 |
Hydralazine-Induced ANCA Vasculitis in the Setting of Acute Clostridium Difficile Infection.
Topics: Adrenal Cortex Hormones; Aged; Antibodies, Antineutrophil Cytoplasmic; Antihypertensive Agents; Clos | 2016 |
An Elderly Man with Fatigue, Dyspnea, and Kidney Failure.
Topics: Aged; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Antineutrophil Cytopla | 2017 |
Blood pressure versus direct mineralocorticoid effects on kidney inflammation and fibrosis in DOCA-salt hypertension.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Desoxycorticosterone; Disease Models, Animal; Dise | 2008 |
Hydralazine-induced ANCA-positive pauci-immune glomerulonephritis: a case report and literature review.
Topics: Antibodies, Antineutrophil Cytoplasmic; Antihypertensive Agents; Female; Glomerulonephritis; Humans; | 2009 |
Hydralazine-induced pulmonary-renal syndrome: a case report.
Topics: Aged; Female; Glomerulonephritis; Glucocorticoids; Hemorrhage; Humans; Hydralazine; Immunosuppressiv | 2012 |
Angiotensin II overcomes strain-dependent resistance of rapid CKD progression in a new remnant kidney mouse model.
Topics: Albuminuria; Anemia; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertens | 2010 |
Hydralazine-induced ANCA vasculitis with pulmonary renal syndrome: a rare clinical presentation.
Topics: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antihypertensive Agents; Glomerulonephri | 2012 |
[Hydrazinophthalazine in the treatment of glomerulonephritis caused by focal sepsis].
Topics: Glomerulonephritis; Hydralazine; Pharyngeal Diseases; Pharynx; Sepsis; Sympatholytics | 1955 |
[Combined serpasil, apresoline and verlloid therapy of hypertensive form of glomerulonephritis].
Topics: Antihypertensive Agents; Glomerulonephritis; Humans; Hydralazine; Hypertension; Reserpine | 1957 |
[Apresoline in the treatment of hypertension caused by glomerulonephritis in children].
Topics: Glomerulonephritis; Humans; Hydralazine; Hypertension | 1957 |
ACUTE GLOMERULONEPHRITIS.
Topics: Blood Chemical Analysis; Child; Convalescence; Edema; Electrocardiography; Erythromycin; Glomerulone | 1964 |
[MEDICAL TREATMENT OF HYPERTENSIVE CRISES].
Topics: Diuretics; Female; Ganglionic Blockers; Glomerulonephritis; Hexamethonium Compounds; Humans; Hydrala | 1964 |
[TREATMENT OF HYPERTENSION DUE TO ACUTE GLOMERULONEPHRITIS WITH PARENTERAL RESERPINE AND HYDRALAZINE].
Topics: Glomerulonephritis; Hydralazine; Hypertension; Hypertension, Renal; Infusions, Parenteral; Kidney; R | 1964 |
THE HEART AND ACUTE GLOMERULONEPHRITIS.
Topics: Child; Diet, Sodium-Restricted; Digitalis Glycosides; Drug Therapy; Glomerulonephritis; Heart Diseas | 1964 |
ACUTE GLOMERULONEPHRITIS IN CHILDREN. A REVIEW OF THIRTY-EIGHT CASES.
Topics: Acute Disease; Child; Drug Therapy; Glomerulonephritis; Hydralazine; Infant; Reserpine; Urine | 1964 |
HEMOLYTIC UREMIC SYNDROME.
Topics: Acute Kidney Injury; Anemia, Hemolytic; Child; Diagnosis; Dialysis; Diarrhea; Drug Therapy; Glomerul | 1965 |
EXPERIENCES WITH THE LONG-TERM USE OF METHYLDOPA ("ALDOMET") IN HYPERTENSION.
Topics: Benzothiadiazines; Blood Pressure Determination; Depression; Drug Therapy; Drug Tolerance; Glomerulo | 1965 |
LUPUS GLOMERULONEPHRITIS. THE EFFECT OF LARGE DOSES OF CORTICOSTEROIDS ON RENAL FUNCTION AND RENAL LESIONS IN TWO CHILDREN.
Topics: Adolescent; Adrenal Cortex Hormones; Cortisone; Drug Therapy; Glomerulonephritis; Guanethidine; Hydr | 1965 |
[THE DETERMINATION OF THE RENAL BLOOD FLOW BY MEANS OF A METHOD OF DILUTION].
Topics: Anuria; Blood Flow Velocity; Dye Dilution Technique; Glomerulonephritis; Humans; Hydralazine; Kidney | 1964 |
[Kidney diseases caused by drugs].
Topics: Acute Kidney Injury; Adult; Anemia; Arthritis, Rheumatoid; Dextrans; Drug-Related Side Effects and A | 1967 |
Rapidly progressive glomerulonephritis after hydralazine.
Topics: Glomerulonephritis; Humans; Hydralazine; Hypertension | 1983 |
Hydralazine-associated glomerulonephritis.
Topics: Adult; Aged; Female; Glomerulonephritis; Humans; Hydralazine; Middle Aged | 1983 |
Immune complex glomerulonephritis in hydralazine-induced SLE.
Topics: Aged; Arteritis; Female; Glomerulonephritis; Humans; Hydralazine; Immune Complex Diseases; Kidney Di | 1984 |
Hydralazine and lupus nephritis.
Topics: Adult; Aged; Female; Glomerulonephritis; Humans; Hydralazine; Hypertension; Immune Complex Diseases; | 1984 |
Renal failure, dyspnea and anemia in a 57 year old woman. Clinicopathologic conference.
Topics: Anemia; Diagnosis, Differential; Dyspnea; Female; Glomerulonephritis; Humans; Hydralazine; Hypertens | 1981 |
[Glomerulonephritis - hydralazine].
Topics: Glomerulonephritis; Humans; Hydralazine | 1984 |
Focal glomerulonephritis in the course of hydralazine-induced lupus syndrome.
Topics: Biopsy; Glomerulonephritis; Humans; Hydralazine; Hypertension; Kidney; Lupus Erythematosus, Systemic | 1984 |
Occurrence of autoantibodies directed against myeloperoxidase and elastase in patients treated with hydralazine and presenting with glomerulonephritis.
Topics: Adult; Antibodies, Antinuclear; Antibody Specificity; Autoantibodies; Fluorescent Antibody Technique | 1994 |
Effects of captopril and hydralazine on progression of adriamycin nephropathy in spontaneously hypertensive rats.
Topics: Animals; Blood Pressure; Body Weight; Captopril; Doxorubicin; Female; Glomerulonephritis; Hematocrit | 1994 |
Autoantibodies to myeloperoxidase in idiopathic and drug-induced systemic lupus erythematosus and vasculitis.
Topics: Adolescent; Adult; Aged; Antibodies, Antineutrophil Cytoplasmic; Antibody Specificity; Autoantibodie | 1994 |
Granulocyte autoantibodies--markers for drug-induced autoimmune adverse effects.
Topics: Antibodies, Antineutrophil Cytoplasmic; Autoantibodies; Autoimmune Diseases; Biomarkers; Glomerulone | 1993 |
Effects of treatment with angiotensin-converting enzyme inhibitor (ACEI) or angiotensin II receptor antagonist (AIIRA) on renal function and glomerular injury in subtotal nephrectomized rats.
Topics: Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Bl | 1997 |
[Hemodynamic parameters and plasma-renin activity following intravenous dihydralazine administration--a contribution to the regulation of renin].
Topics: Adolescent; Adult; Arterial Occlusive Diseases; Dihydralazine; Female; Glomerulonephritis; Humans; H | 1978 |
Therapy and prognosis of hypertension in chronic nephritis.
Topics: Adult; Aldosterone; Angiotensin II; Blood Volume; Catecholamines; Chronic Disease; Creatinine; Extra | 1975 |
Antibodies to neutrophil granulocyte myeloperoxidase and elastase: autoimmune responses in glomerulonephritis due to hydralazine treatment.
Topics: Autoantibodies; Cytoplasm; Enzyme-Linked Immunosorbent Assay; Female; Fluorescent Antibody Technique | 1991 |
Anti-glomerular basement membrane nephritis due to hydralazine.
Topics: Autoantibodies; Basement Membrane; Glomerulonephritis; Humans; Hydralazine; Immunoglobulin G; Kidney | 1991 |
Comparison of BAY e 5009 (nitrendipine) with dihydralazine in Wistar rats with experimentally induced nephritis.
Topics: Animals; Antibodies; Basement Membrane; Blood Pressure; Dihydralazine; Glomerulonephritis; Hydralazi | 1988 |
Effects of antihypertensive drugs on glomerular morphology.
Topics: Animals; Antihypertensive Agents; Enalapril; Glomerulonephritis; Glomerulosclerosis, Focal Segmental | 1989 |
Hydralazine-induced glomerulonephritis.
Topics: Diagnosis, Differential; Female; Glomerulonephritis; Humans; Hydralazine; Male | 1985 |
Dietary protein restriction and renal injury in the spontaneously hypertensive rat.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Chlorothiazide; Dietary Proteins; Glo | 1989 |
Therapeutic implications of hypertension-induced glomerular injury. Comparison of enalapril and a combination of hydralazine, reserpine, and hydrochlorothiazide in an experimental model.
Topics: Animals; Enalapril; Glomerular Filtration Rate; Glomerular Mesangium; Glomerulonephritis; Glomerulos | 1985 |
Side-effects in long-term treatment with hydralazine.
Topics: Aged; Female; Glomerulonephritis; Humans; Hydralazine; Hypertension; Lupus Erythematosus, Systemic; | 1986 |
Rapidly progressive nephritis in patients taking hydralazine.
Topics: Female; Glomerulonephritis; Humans; Hydralazine; Male; Middle Aged; Time Factors | 1986 |
[Adverse effects of prolonged treatment with hydralazine--a retrospective study].
Topics: Aged; Female; Glomerulonephritis; Humans; Hydralazine; Kidney; Lupus Erythematosus, Systemic; Male; | 1986 |
Hydralazine-associated glomerulonephritis.
Topics: Antibodies, Antinuclear; Female; Fluorescent Antibody Technique; Glomerulonephritis; Humans; Hydrala | 1985 |
Periodic dialysis in terminal uremia.
Topics: Adolescent; Adult; Anemia; Arthritis; Child; Female; Gastrointestinal Hemorrhage; Glaucoma; Glomerul | 1967 |
[Hypertension of renal origin].
Topics: Clonidine; Diet, Sodium-Restricted; Glomerulonephritis; Humans; Hydralazine; Hypertension, Renal; Ki | 1973 |
Galactorrhea and Parkinson-like syndrome: an adverse effect of alpha-methyldopa.
Topics: Adolescent; Amenorrhea; Female; Glomerulonephritis; Humans; Hydralazine; Hypertension; Kidney Transp | 1970 |
Oliguric acute renal failure in malignant hypertension.
Topics: Acute Kidney Injury; Adult; Anuria; Blood Urea Nitrogen; Diagnosis, Differential; Female; Glomerulon | 1972 |
Furosemide in the treatment of acute post-streptococcal glomerulonephritis.
Topics: Bicarbonates; Blood Pressure Determination; Blood Urea Nitrogen; Child; Chlorides; Creatinine; Edema | 1969 |
Hypertension in end-stage renal disease.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Black People; Blood Pressure; Body Weight; Chronic | 1969 |
Chronic hemodialysis in a pre-adolescent.
Topics: Adolescent; Child; Diet, Sodium-Restricted; Female; Glomerulonephritis; Hematocrit; Humans; Hydralaz | 1966 |